Decision-making perspectives

GetReal aims to show how new, robust methods of real-world evidence (RWE) collection and synthesis could be adopted earlier in pharmaceutical research and development (R&D) and the decision-making process for new medicines.

There are a range of perspectives which influence the definition, valuation and measurement of relative effectiveness. Ultimately, the perspectives of greatest importance are those of the patient (and carer) and clinician. These will be reflected in the decision-making perspectives of regulatory and health technology assessment (HTA) agencies as well as manufacturers (pharmaceutical R&D), which are the main focus of this RWE Navigator. Other perspectives include those of health care payers (insurers), health care providers, employers and health policy makers.

[TABS_R id=231]